Novartis in plant contract dispute with Chinese CDMO Porton
A Novartis cross-border partnership is turning into a standoff. The Swiss pharma has unilaterally terminated a plant leasing…
Samsung Biologics Acquires Swiss CDMO for approximately $1.8 Billion, Making a Major Push into the Obesity Drug Market — BigGo Finance
Samsung Biologics (207940) is investing approximately 2.7 trillion won (approximately $1.8 billion) to acquire PolyPeptide Group, a global…
Samsung Biologics Acquires Swiss PolyPeptide Group for approximately $1.8 Billion, Targeting Obesity Drug Market — BigGo Finance
Samsung Biologics is making a blockbuster acquisition of PolyPeptide Group AG, a Swiss peptide contract development and manufacturing…
Samsung Targets Swiss CDMO PolyPeptide in $1.8 Billion Deal
Samsung Biologics of South Korea has offered shareholders CHF44.31 per share in cash, valuing PolyPeptide’s equity at approximately…
Samsung Biologics Bets $1.8 Billion on ‘K-Obesity Drug’ Play with Swiss PolyPeptide Acquisition — BigGo Finance
Samsung Biologics has thrown its hat into the rapidly growing global obesity treatment market, committing 2.7 trillion won…